Nontraditional Risk Factors For Heart Disease Require More Study
This article was originally published in The Gray Sheet
Executive Summary
More evidence is needed to determine whether screening for nine nontraditional risk factors would help better define patients' risk of coronary heart disease, according to an Oct. 6 assessment by the U.S. Preventive Services Task Force
You may also be interested in...
JUPITER Not Enough To Expand CRP Testing Indication, Experts Say
Experts are not ready to call for an expansion of high-sensitivity C-reactive protein (hsCRP) testing, even though new trial results show elevated CRP testing can identify patients with low cholesterol who might benefit from statin drugs
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.